TP53 and myelodysplastic syndrome: The latest WHO edition (2022) incorporated subtypes, based on their molecular characteristics, such as the MDS with biallelic TP53 inactivation (MDS-biTP53), or MDS with low blasts and SF3B1 mutation (MDS-SF3B1), which replaced the previous entity “refractory anemia with ring sideroblasts”, and finally the Clonal Cytopenia of Undetermined Significance (CCUS), which is defined as CHIP in the presence of one or more persistent cytopenias that are otherwise unexplained (13).